Barclays Initiates Coverage On Tvardi Therapeutics with Overweight Rating, Announces Price Target of $61
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Barclays analyst Etzer Darout initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces Price Target of $61.
Barclays analyst Etzer Darout initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Overweight rating and announces Price Target of $61.